Day: May 15, 2025

PHOENIX, May 15, 2025 (GLOBE NEWSWIRE) — QuoteMedia, Inc. (OTCQB: QMCI), a leading provider of market data and financial applications, announced financial results for the quarter ended March 31, 2025. QuoteMedia provides banks, brokerage firms, private equity firms, financial planners and sophisticated investors with a more economical, higher quality alternative source of stock market data and related research information. We compete with several larger legacy organizations and a modest community of other smaller companies. QuoteMedia provides comprehensive market data services, including streaming data feeds, on-demand request-based data (XML/JSON), web content solutions (financial content for website integration) and applications such as Quotestream Professional desktop and mobile.  Highlights for Q1 2025 include the following:Quarterly...

SAN DIEGO, May 15, 2025 (GLOBE NEWSWIRE) — Beam Global, (Nasdaq: BEEM), (the “Company”), a leading provider of innovative and sustainable infrastructure solutions for the electrification of transportation and energy security, today announced its first quarter results for the period ended March 31, 2025. Q1 2025 Financial HighlightsRevenue CAGR 60% for trailing 60 months Commercial Revenues increased 41% over Q1 2024 Positive GAAP Gross Margin 8% Adjusted non-GAAP Gross Margin, net of non-cash costs 21% Net cash used in Operations for Q1 2025 $1.8 million vs. Q1 2024 $3.0 million Backlog of $6.3 million Debt free and $100 million line of credit available and unusedQ1 2025 and Recent Operational HighlightsIn Q1 2025 we shipped EV ARC™ units, ARC Mobility™ trailers, energy storage systems (ESS), lighting poles...

Q1 2024 net product revenues increased 55% year-over-year to $163.6 thousand. Gross profit increased 124% to $90.3 thousand.WASHINGTON, May 15, 2025 (GLOBE NEWSWIRE) — 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, reported today their financial results for the first fiscal quarter of the 2025 year, ended March 31, 2025. Financial Highlights for the Quarter Ended March 31, 2025:Net product revenues increased approximately 55% from $105.7 thousand for the first quarter of 2024 to approximately $163.6 thousand for the first quarter of 2025; the Company credits growth from domestic sales of ARAKODA®. The Company achieved a gross profit of approximately $90.3 thousand in the first quarter of 2025, compared with an approximate...

Reverse Prior-Year Nine-Month Net Loss of $5.0 Million to Modest Net Profit KUALA LUMPUR, Malaysia, May 15, 2025 (GLOBE NEWSWIRE) — Treasure Global Inc. (NASDAQ: TGL) (“Treasure Global” or the “Company”), a leading e-commerce platform operator, today announced its financial results for the third quarter ended March 31, 2025. Key Financial HighlightsRevenue for the third quarter was $0.67 million, a 58% decrease from $1.60 million in the third quarter of fiscal 2024, but increased by 121% quarter-over-quarter. Gross profit reached $0.49 million, a 41% year-over-year increase, with gross profit margin rising to 73% from 14% in the prior-year quarter. Operating loss narrowed significantly to $43 thousand, compared to $1.37 million in the third quarter of fiscal 2024. Net income was $1.26 million, a significant turnaround from a...

Year-over-year product revenue increased 8%, and year-over-year operating expenses decreased 5% as Vivos sets the stage for its Sleep Center of Nevada acquisition and continued advancement of its new marketing and distribution model Management to Host Conference Call today at 5:00 pm ET LITTLETON, Colo., May 15, 2025 (GLOBE NEWSWIRE) — Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA) in adults, and moderate to severe OSA in children ages 6 – 17), today reported financial results and operating highlights for the first quarter ended March 31, 2025. Vivos believes its...

Ibrexafungerp clinical hold lifted by the FDA. SCYNEXIS working to resolve a disagreement with GSK involving the restart of the MARIO study. GSK remains committed to the commercialization of Brexafemme.Hansoh recently received Chinese (NMPA) approval for ibrexafungerp in the treatment of acute VVC. SCYNEXIS will receive a milestone payment from Hansoh upon commercialization as well as royalties of approximately 10% on China sales.Presented positive preclinical data for its second-generation fungerp candidate, SCY-247, at the European Society of Clinical Microbiology and Infectious Disease (ESCMID) meeting; Company expects to report initial Phase 1 data for SCY-247 in Q3 2025.   SCYNEXIS ended Q1 2025 with cash, cash equivalents and investments of $53.8 million and projects a cash runway into Q3 2026.JERSEY CITY, N.J., May 15,...

Longanesi First Gas Sales Have Been Achieved First Quarter 2025 and Recent Company Highlights:AleAnna reported basic and diluted net loss per common share of ($0.05) for the quarter ended March 31, 2025, compared with ($3.41) for the same period in 2024. AleAnna ended the quarter with cash and cash equivalents of approximately $27.8 millionDALLAS, May 15, 2025 (GLOBE NEWSWIRE) — AleAnna, Inc. (“AleAnna” or “the Company”) (NASDAQ: ANNA) today announced financial results for the first quarter of 2025. While revenue from Longanesi field production was not recognized during the quarter, in May 2025 AleAnna achieved first sales and the Company expects to report revenue from the Longanesi field as a part of second quarter results. For the first quarter 2025, AleAnna reported net loss of $2.0 million. This amounts to a basic and diluted...

Reports Increased CompuFlo® Adoption Following Assignment of Favorable Medicare Payment Rates; Expands Federal Outreach Following FSS Contract Award ROSELAND, N.J., May 15, 2025 (GLOBE NEWSWIRE) — Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today provided a business update and reported financial results for the first quarter ended March 31, 2025. Neal Goldman, Chairman and Interim Chief Executive Officer of Milestone Scientific, commented, “We are encouraged by the growing momentum in our medical segment, where first quarter results reflect increased traction for the CompuFlo® Epidural System. During the quarter, we were pleased to see new practices integrating CompuFlo into their workflows. These adoptions reflect both...

SAN JOSE, Calif., May 15, 2025 (GLOBE NEWSWIRE) — Firsthand Technology Value Fund, Inc. (OTCQB: SVVC) (the “Fund”), a publicly traded venture capital fund that invests in technology and cleantech companies, announced today its financial results for the quarter ended March 31, 2025. As of March 31, 2025, the Fund’s net assets were approximately $0.8 million, or $0.12 per share, compared with net assets of approximately $1.1 million, or $0.15 per share as of December 31, 2024. As of March 31, 2025, the Fund’s portfolio included public and private securities valued at approximately $0.7 million, or $0.10 per share, which includes approximately $0.07 per share in cash and cash equivalents. Portfolio Summary (as of 3/31/25)Investment Fair Value1, Fair Value per Share1,2Equity/Debt Investments $0.24 million $0.04Cash/Cash Equivalents $0.45...

LOS ANGELES, May 15, 2025 (GLOBE NEWSWIRE) — Nova LifeStyle, Inc. (NASDAQ: NVFY) (“Nova LifeStyle” or the “Company”) today announced financial results for the first quarter ended March 31, 2025. Mr. Xiaohua Lu, newly appointed Chief Executive Officer of Nova LifeStyle, stated, “This is a very exciting time for Nova LifeStyle as we strategize moving forward among the uncertainty related to tariffs and the impact on the furniture industry. The first quarter showed our products are well received considering an increase in revenues, all of which can be attributed to our higher margin product lines, which also improved our gross profit numbers and margins. As we plan for the remainder of 2025 and beyond, I believe it starts with a product line that is forward thinking and anticipating new trends. As the new CEO, I am eager to work with...